VA/DoD CLINICAL PRACTICE GUIDELINE FOR OPIOID THERAPY FOR CHRONIC PAIN
2lfFhbO
2lfFhbO
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>VA</strong>/<strong>DoD</strong> Clinical Practice Guideline for Opioid Therapy for Chronic Pain<br />
Table E-3. Key Question Specific Comparators<br />
Question<br />
Comparators<br />
1 Patients without a co-occurring medical or mental health condition on LOT<br />
2 Comparison groups that vary by LOT dosage and length of opioid use, other factors<br />
3<br />
4<br />
5<br />
No OT (including placebo) or other pain management strategies<br />
Other modalities:<br />
• Non-opioid medications (e.g., non-steroidal including compounded topical preparations)<br />
• Physical interventions (e.g., physical therapy, active/passive exercise, ultrasound stimulation,<br />
chiropractic, osteopathic manipulation therapy)<br />
• Behavioral/mental health interventions EXAMPLES:<br />
• CBT<br />
• Dialectical behavior therapy (DBT)<br />
• Mindfulness<br />
• Acceptance and commitment therapy (ACT)<br />
• Complementary and alternative interventions EXAMPLES:<br />
• Acupuncture<br />
• Chiropractic interventions<br />
No OT (including placebo) or other pain management strategies<br />
Other modalities:<br />
• Non-opioid medications (e.g., non-steroidal including compounded topical preparations)<br />
• Physical interventions (e.g., physical therapy, active/passive exercise, ultrasound stimulation,<br />
chiropractic, osteopathic manipulation therapy)<br />
• Behavioral/ mental health interventions (e.g., CBT, ACT, mindfulness, DBT)<br />
• Complementary and alternative interventions<br />
Long-acting opioid drugs or combination short and long-acting drugs (See list)<br />
Other route of administration/delivery alternatives<br />
Non abuse-deterrent formulations<br />
Other opioids<br />
No use of buprenorphine<br />
No use of methadone<br />
6 Opioid therapy alone<br />
7 No mitigation strategy or other mitigation strategy<br />
8 No treatment for OUD or other treatment for OUD<br />
9 Different tapering strategy or schedule<br />
d. Outcomes<br />
For the treatment and management questions (KQ 3–9), the following outcomes were of interest in the<br />
systematic review:<br />
• Pain relief<br />
• Quality of life<br />
• Cognitive/functional status<br />
• Mortality<br />
• Opioid abuse/misuse<br />
February 2017 Page 110 of 192